Previous
Previous Product Image

Oakstone Comprehensive Review of Pain Medicine 2020

40 $
Next

American Society for Clinical Pathology 2020 Virtual Meeting

40 $
Next Product Image

Alzheimer’s Association International Conference 2019

20 $

+ Include: 581 videos, size: 26.2 GB

+ Target Audience: pathologist, neurologist

Description

+ Include: 581 videos, size: 26.2 GB

+ Target Audience: pathologist, neurologist

+ Sample video: contact me for sample video

+ Topics:

02-01-01 – Sleep, Brain, and Cognition.mp4
02-02-01 – Alzheimer’s Disease Blood-Based Biomarkers and AD Control.mp4
03-02-01 – The Epidemiology of Diversity and Dementia.mp4
05-01-01 – Microglia in Neurodegenerative Conditions.mp4
05-02-01 – Precision Medicine, Population Neuroscience and Comprehensive Care Partners to Develop and Deliver Effective Prevention.mp4
DB-01-01 – Temporal Trajectories of In Vivo Tau and Amyloid-á Accumulation in Alzheimer’s Disease.mp4
DB-01-02 – Vascular Risk Factors and Multimodal Neuroimaging Biomarkers Preliminary Analyses from the Multi-Ethnic Study of Atherosclerosis.mp4
DB-01-03 – Global Cortical [F18]Flortaucipir Association with the Top 20 Alzheimer’s Disease Risk Genes.mp4
DB-01-04 – Cerebral Amyloid Angiopathy Is More Severe in Autosomal Dominant AD Cases with Cerebral Microhemorrhages.mp4
DT-01-01 – BAN2401 In Early Alzheimer’s Disease Neurodegeneration Biomarker Analysis From Randomized Phase 2 Study.mp4
DT-01-02 – Continued large amyloid PET reductions at 36 months in the gantenerumab open-label extension studies.mp4
DT-01-03 – Longitudinal amyloid, neurodegeneration and cognition in pre-dementia elderly individuals with different ATN profiles.mp4
DT-01-04 – Diagnostic performance of [18F]RO948 PET in the separation of Alzheimer’s disease.mp4
DT-01-05 – Temporal Lobe Quantitation of Flortaucipir PET Images May Improve Detection of Intermediate Neurofibrillary Tangle Pathology.mp4
DT-01-06 – Association of APOE e2 Genotype with Neuroprotection A Trans-diagnostic Study of 1557 Brains in the NACC v 10 Data Base.mp4
DT-02-01 – Repurposing FDG-PET as a diagnostic tool for Alzheimer’s-related TDP-43-proteinopathy.mp4
DT-02-02 – TOMMORROW Results from a Phase 3 Trial to Delay the Onset of MCI Due to AD and Qualify a Genetic Biomarker Algorithm.mp4
DT-02-03 – Open Label Extension Results from a Phase II III Trial of Intranasal Insulin.mp4
DT-02-04 – A Randomized Double-Blind Placebo-Controlled Phase 2A Clinical Trial of NA-831 in Patients with MCI and early onset of Alzheimer’s disease.mp4
DT-02-05 – A Novel Therapeutic (NTRX-07) Targeting Neuroinflammation in Alzheimer’s disease is Undergoing Phase I trials.mp4
DT-02-06 – A Novel Small Molecule Inhibitor of the Discoidin Domain Receptors (DDR) Reduces Tau and Amyloid-á and Improves Cognition in Models.mp4
EC-01-01 – The Impact of DNA Damage, Transcription Stress and Nutrition on Aging, Protein Aggregation and Neurodegeneration.mp4
EC-01-02 – Transposable Element Activation in Tauopathy.mp4
EC-01-03 – Neuronal and Glial DNA Double Strand Breaks in Early Stages of Alzheimer’s Disease.mp4
EC-01-04 – Age-Related Accumulation of DNA Damage in Microglia and Its Neurotoxic Consequences.mp4
EC-02-01 – A Fundamental Biophysical Process Contributing to Disease Mechanisms Liquid-Liquid Phase Separation of Tau.mp4
EC-02-02 – RNA Metabolism in Stress and Disease RNA Translation, RNA Binding Proteins, RNA Granules.mp4
EC-02-03 – The Role of Stress Granules and RNA Metabolism in the Pathophysiology of Tau.mp4
EC-02-04 – Mechanisms of Accumulation of Pathological TDP-43 In Vivo.mp4
EC-03-01 – Pro Side Presentations (10 minutes each).mp4
EC-04-01 – Panel Discussion.mp4
F1-01-01 – Value of Study Partner Reports to Assess and Predict Cognitive Impairment and Decline.mp4
F1-01-02 – Item-Level Comparison of Participant and Study Partner Report on the Cognitive Function Index By Amyloid PET from the A4 Study.mp4
F1-01-03 – Online Study Partner-Reported Subjective Decline Is Associated with á-Amyloid and Clinical Diagnosis.mp4
F1-01-04 – Why Is the Study Partner Requirement a Barrier to Recruitment in Preclinical Alzheimer’s.mp4
F1-02-01 – Subthreshold Amyloid Accumulation Does It Predict Memory Decline.mp4
F1-02-02 – Biological Consequences of Subthreshold Amyloid Accumulation.mp4
F1-02-03 – Effects of Amyloid Accumulation on Neurocognitive Performance in Healthy Middle-Aged and Older Adults.mp4
F1-02-04 – Multimodal Evidence for Early Amyloid Accumulation.mp4
F1-03-01 – CSF Biomarkers Related to Neurodegeneration As Predictors of Cognitive Progression in MCI and Elderly Controls.mp4
F1-03-02 – The at(N) Framework in the Wisconsin Registry for Alzheimer’s Prevention Evidence from PET Imaging.mp4
F1-03-03 – Distinct Contributions of Baseline and Longitudinal Amyloid PET Measures to Memory.mp4
F1-03-04 – Aá-Positivity Predicts Cognitive Decline but Cognition Also Predicts Progression to Aá-Positivity.mp4
F1-04-01 – Frequency of Subjective Cognitive Decline Criteria in Stage 2 of the New NIA-AA Framework.mp4
F1-04-02 – Harmonizing Subjective Cognitive Decline Measurements across 19 International Cognitive Aging Studies.mp4
F1-04-03 – ATN Biomarker Model As a Determinant of Cognitive Decline and Incident Clinical Progression in Subjective Cognitive Decline.mp4
F1-04-04 – The SCD-Well Randomized Controlled Trial Effects of a Mindfulness-Based Intervention Versus Health Education.mp4
F1-05-01 – Lab-Related Pre-Analytical Factors Influencing Plasma Amyloid Beta Concentrations.mp4
F1-05-02 – Patient-Related Pre-Analytical Factors Influencing Plasma Amyloid Beta Concentrations.mp4
F1-05-03 – The 1946 Cohort – Relationships between Cerebral Amyloid Pathology Using Two Independent Methods for Plasma Amyloid Beta Measurement.mp4
F1-05-04 – The Global Alzheimer’s Association Round Robin Study on Plasma Amyloid Beta Methods.mp4
F1-06-01 – Sleep-Wake Behavior in the 4Repeat Tauopathy- Progressive Supranuclear Palsy.mp4
F1-06-02 – Neurobiological Basis of Sleep and Wake Dysfunction in AD and Other Tauopathies The Role of the Neuromodulatory System.mp4
F1-06-03 – Altered Sleep-Wake Mechanisms in Neurodegenerative Disease Similarities and Difference between Lewy Body Disease and Narcolepsy.mp4
F1-06-04 – Panel Discussion (including the audience brainstorming on the best ways to address gaps).mp4
F1-07-01 – Astroglial and Microglial Modulation of Neural Functions in Models of Alzheimer’s Disease.mp4
F1-07-03 – Alzheimer’s Susceptibility Genes Implicate Microglial Activity.mp4
F1-07-04 – Using Human iPSC Models to Probe TREM2 Function.mp4
F1-08-01 – Ethnic Differences in Cognition and Age in People Diagnosed with Dementia A Study of Electronic.mp4
F1-08-02 – Using Racial Ethnic Comparisons to Evaluate Unmeasured Confounding.mp4
F1-08-03 – The Effect of Ethnicity on the Sensitivity of General Hospital Dementia Records Cohort Study Using English Electronic Health Records.mp4
F1-08-04 – Panel Discussion.mp4
F2-01-01 – Neurodevelopmental Differences and Environmental Insults Inversely Correlate with Age of Onset in Alzheimer’s Disease.mp4
F2-01-03 – Am I the Right Way up Investigating Balance Problems in Posterior Cortical Atrophy.mp4
F2-01-04 – Paradoxical Aging in Alzheimer’s Disease.mp4
F2-02-01 – Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimer’s Disease.mp4
F2-02-02 – Understanding the Role of SORL1 and Endosomal Network Dysfunction in Alzheimer’s Disease.mp4
F2-02-03 – Alzheimer’s Disease Modeling and Drug Screening Using Patients-Derived iPSCs with Different ApoE Genotypes.mp4
F2-02-04 – Targeting Aberrant Cholesterol Metabolism in Alzheimer’s Disease; Drug Discovery in iPSC-Derived Neurons..mp4
F2-03-01 – Clinical Meaningfulness of Short-Term Cognitive Decline on the Preclinical Alzheimer’s ….mp4
F2-03-02 – Optimizing Cognitive Outcomes for Biomarker Positive Individuals at Different Clinical Stages of Alzheimer’s Disease According.mp4
F2-03-03 – Adcoms A Sensitive Measure of Disease Progression in Early AD Supporting Better Development Decisions.mp4
F2-03-04 – Assessing Clinical Meaningfulness of Outcomes in the Alzheimer’s Prevention Initiative Generation Program.mp4
F2-04-01 – Neuropathology of VCID A Classical Landscape.mp4
F2-04-02 – Neuropathology Big Data. It’s All VCID.mp4
F2-04-03 – Digital Molecular Pathology. Axonal Damage and Small Vessel Disease.mp4
F2-04-04 – Leveraging Neuropathology to Integrate with RNA and Other Omics.mp4
F2-05-01 – Sleep Duration over 28 Years and Grey Matter Volumes A Prospective Cohort Study.mp4
F2-05-02 – How Does Sleep-Wake Disturbance Relate to Neuropsychological and Neuroimaging Markers in Older People at Risk for Dementia.mp4
F2-05-03 – Sleep Medication Use and Risk of Dementia in a Biracial Cohort of Older Adults.mp4
F2-05-04 – Slow Wave Sleep Enhancers As a Potential Therapeutic Approach in Delaying Cognitive Decline in Alzheimer’s Disease.mp4
F2-06-01 – Major Differences between the Self-Assembly, Seeding Behavior, and Interaction with Modulators.mp4
F2-06-02 – Trafficking of Tau Oligomers through the Plasma Membranes of Neurons and Astrocytes Is Critical for Their Synaptotoxicity.mp4
F2-06-03 – Amyloid á-Protein Oligomers Promote the Uptake of Tau Fibril Seeds Potentiating ….mp4
F2-06-04 – Polymorphism and Toxic Interactions between Soluble Amyloid Oligomers and Tau.mp4
F2-07-01 – Blood Amyloid-Beta Predicts Amyloid PET Conversion.mp4
F2-07-02 – Recent Findings of Novel Blood Components Amyloid-Beta Measures.mp4
F2-07-03 – Fully Automated Plasma Assays As Screening Tests for Early Alzheimer-Related á-Amyloid.mp4
F2-07-04 – Plasma Amyloid Beta 1-42 and 1-40 Measured By a Novel Simoa Assay As a Diagnostic Tool.mp4
F2-08-01 – Sleep Timing and Risk of Dementia Among Chinese Elderly in an Urban Community.mp4
F2-08-02 – Local Slow Wave Measures during Nrem Slow Wave Sleep Accurately Track á-Amyloid Status.mp4
F2-08-03 – Effect of Sleep on CSF Tau and p-Tau.mp4
F2-08-04 – Obstructive Sleep Apnea, Cognition and AD Neurodegeneration..mp4
F3-01-01 – The Diagnostic Framework for Alzheimer’s Disease.mp4
F3-01-02 – Capturing Cognitive Impairment at the Preclinical Stage of Alzheimer’s Disease Using Digital Technology.mp4
F3-01-03 – The Integrated Cognitive Assessment – Employing Artificial Intelligence for the Detection of Cognitive Impairment.mp4
F3-01-04 – Panel Discussion.mp4
F3-02-01 – The Effect of Race on Driving Performance, Self-Reported and Naturalistic Driving Behavior Among Older Adults.mp4
F3-02-02 – The Stress and Resilience in Dementia (STRIDE) Study Social-Biological Dimensions of ADRD Risk, Disparity, and Resilience.mp4
F3-02-03 – Creating Dementia-Friendly Faith Villages to Support African American Families.mp4
F3-02-04 – It’s Tied to a Purpose A Culturally Celebratory Approach to Motivate Physical and Social Activity Among African Americans.mp4
F3-03-01 – Unveiling the Neural Correlates of Cognitive and Functional Impairments in Ageing and Dementia Relying on Mobile EEG Technologies.mp4
F3-03-02 – Studying the Effects of Repetitive Paired Associative Stimulation on Dlpfc Plasticity.mp4
F3-03-03 – Replicating Lab Electrophysiology with Older Users in the Home, Using Gamified Dry EEG.mp4
F3-03-04 – Exploration of EEG Event-Related Potentials in a Memory Disorders Clinic.mp4
F3-04-01 – Barriers and Facilitators for Retaining Independence at Home from a UK Multi- Stakeholder Perspective.mp4
F3-04-02 – Inequalities in Care Provision for People with Dementia from Different Ethnic Minority Groups.mp4
F3-04-03 – Co-Designing a Training Programme for Paid Home Carers to Deliver Dementia Specific Care to People at Home.mp4
F3-04-04 – Stakeholder Perspectives on How the Home Care Sector Can Support People to Live Well with Dementia..mp4
F3-05-01 – Vascular Cognitive Disorders in L M I Cs Challenges and Opportunities in Studying Diverse Populations.mp4
F3-05-02 – Vascular Risk Factors for a D R D in Latin America A Focus on the Caribbean.mp4
F3-05-03 – Vascular Risk Factors and Multimodal Neuroimaging Biomarkers Preliminary Analyses.mp4
F3-05-04 – White Matter Hyperintensities and Cognition The Moderating Role of Quality of Education in a Multiracial Community Sample.mp4
F4-01-01 – Plasma Test for Amyloid Risk Screening The C2N sponsored PARIS Add-on Study to IDEAS.mp4
F4-01-02 – Increasing the Impact of the Ideas Study Using Brain Health Registry Online Data Collection.mp4
F4-01-03 – Caregivers’ Reactions and Experiences Imaging Dementia-Evidence for Amyloid Scanning (CARE IDEAS).mp4
F4-01-04 – Amyloid Neuroimaging and Genetics Initiative A Resource for Investigators.mp4
F4-01-05 – Racial and Ethnic Differences in Amyloid PET Positivity in the IDEAS Study.mp4
F4-02-01 – Trials and Tribulations of Tau PET Imaging.mp4
F4-02-03 – Tau Fluid Biomarkers State-of-the-Art and Novel Findings in AD and Primary Tauopathies.mp4
F4-02-04 – CSF and PET Measures for Tau in Different Stages of Alzheimer’s Disease.mp4
F4-03-01 – Neuropathological Features Underlying Ante-Mortem Cholinergic Basal Forebrain and Medial ….mp4
F4-03-02 – Neuropathological Substrate of Imaging Biomarkers – Validating Neuroimaging Biomarkers in AD.mp4
F4-03-03 – Selectivity of PET Amyloid Imaging Ligands in the Alzheimer’s Disease Neuropathology Spectrum.mp4
F4-03-04 – Autopsy Validation of Amyloid and Tau PET in Clinical Populations.mp4
F4-04-01 – Trial Design, Data Sharing Risk Mitigation, and Baseline Clinical and Cognitive Data from the API.mp4
F4-04-02 – Age-Related Changes in Baseline Cognitive Measures in Unimpaired PSEN1- E280A.mp4
F4-04-03 – Relationships between Baseline Brain Imaging Biomarker Measurements.mp4
F4-04-04 – Association between Cerebral Amyloidosis and Worse Cognitive Performance.mp4
F4-05-02 – Comparison of Variables Associated with CSF Neurofilament, Total-Tau, and Neurogranin in a Community-Based Study.mp4
F4-05-03 – Blood Neurofilament Light (NFL) – a Sensitive but Slow-Release Biomarker.mp4
F4-05-04 – Serum Neurofilaments As Therapy Response Markers in Neurodegenerative Diseases.mp4
F4-06-01 – The Rowland Universal Dementia Assessment Scale A Cross-Cultural Screening Measure for Dementia Clinical Trials.mp4
F4-06-02 – Building Cognitive Reserve in Resource-Limited Settings Evidence from the Health and ….mp4
F4-06-03 – Staging of Cognitive Impairment and Dementia in Low-Educated Elderly.mp4
F4-06-04 – Detecting Dementia in Older, Ethnically Diverse Residents in Rural Subsidized Housing.mp4
F5-01-01 – The Role of Lipid Mediators in Neuroinflammation and Preoperative Neurocognitive Disorders.mp4
F5-01-03 – Neurofilament Light in a Mexican American Cohort.mp4
F5-01-04 – Inflammation As a Potential Shared Mechanism for Postoperative Delirium and Long-Term Cognitive Decline in Older Adults Undergoing.mp4
F5-02-01 – The Interaction of Genetic Admixture and ApoE4. Implications for Cognitive Decline in Alzheimer Disease..mp4
F5-02-02 – Higher Literacy Associates with Better Brain Structure and Cognition in Middle-Aged Individuals.mp4
F5-02-03 – Factors Impacting Loss-to-Follow-up from a Memory Care Center A Study of Potential Palliative Care Needs.mp4
F5-02-04 – Advanced Directive and POLST Utilization in Decedents with Dementia Previously Seen at a Memory Center.mp4
FTS1-01-01 – Introduction to LATE.mp4
FTS1-01-02 – The Pathology of LATE.mp4
FTS1-01-03 – Public Health Impact and Cognition Associated with LATE Neuropathology.mp4
FTS1-01-04 – LATE Biomarkers and Impact on Alzheimer’s Prevention and Treatment Trials.mp4
FTS1-01-05 – Panel Discussion LATE into the World of Alzheimer’s Dementia Nomenclature to Advance Science amidst Multiple Stakeholders.mp4
FTS2-01-01 – Panel Presentation.mp4
FTS3-01-01 – Umibecestat (CNP520) Is Not Associated with Changes in Hippocampal Morphology.mp4
FTS3-01-02 – Subgroup Populations in Amaranth, a Randomized Phase 23 Study in Early Alzheimer’s Disease with Lanabecestat.mp4
FTS3-01-03 – Performance on Exploratory Efficacy Variables in Amaranth, a Randomized Phase 23.mp4
FTS3-01-04 – Final Efficacy, Safety and Biomarker Results of the Phase 2b3 .mp4
FTS3-01-05 – Further Analyses of Cognitive Outcomes in the Apecs Phase-3 Trial of Verubecestat in Prodromal AD.mp4
FTS3-01-06 – Current Update on Elenbecestat in Alzheimer”s Disease.mp4
FTS3-01-07 – Panel Discussion.mp4
FTS5-01-02 – Correlating Cognitive Outcomes with Patient Specific Biomarkers in Alzheimer’s Disease.mp4
FTS5-01-03 – A Pharmacokinetic Pharmacodynamic Evaluation of Imaging Biomarkers of Alzheimer”s Disease.mp4
FTS5-01-04 – The Amyloid Hypothesis Latest Update in the Context of Recent Trial Evidence.mp4
IC-01-01 – [Alzheimer’s Imaging Consortium] Plenary Session What Have We Learned.mp4
IC-02-01 – Grey Matter Connectivity Trajectories across the Alzheimer’s Disease Continuum and Associations with Cognitive Decline.mp4
IC-02-02 – Longitudinal Evaluation of Tau Propagation Using [18f]MK-6240.mp4
IC-02-03 – Mild Cognitive Impairment Progressing to Dementia with Lewy Bodies Regional Atrophy Rates and Relationship to AV-1451 Uptake.mp4
IC-02-04 – Novel Measures of Longitudinal Change in Medial Temporal Lobe Subregions Discriminate Preclinical Alzheimer’s Disease.mp4
IC-02-05 – Gender Differences in the Association between Longitudinal Brain Changes and Baseline Levels of CSF.mp4
IC-03-01 – Plenary Session Preclinical Cognitive Decline Is Related to Tau and Amyloid Imaging Profiles in a Risk-Enriched Cohort.mp4
IC-04-01 – The Search for Pathologically Valid Imaging Biomarkers – AD Pathology Comes Not Alone.mp4
IC-04-02 – Ante-Mortem Volume Loss Mirrors TDP43 Staging in Non-FTLD Older Adults.mp4
IC-04-03 – Utility of MRI in Detection of Atrophy in Hippocampal Sclerosis of Aging.mp4
IC-04-04 – Iron, Neurodegeneration, Tau, and Amyloid in Patients with Alzheimer’s Disease..mp4
IC-04-05 – Cross-Sectional and Longitudinal Medial Temporal Lobe Subregional Atrophy in Suspected ….mp4
IC-05-01 – Debate MRI Versus PET Which Imaging Modality Provides the Best Biomarker and for Which Purpose.mp4
IC-06-01 – Assessment of Longitudinal Amyloid Load Change in Down Syndrome.mp4
IC-06-02 – Associations between Aá and Tau in Adults with Down Syndrome.mp4
IC-06-03 – Spatial Associations of Aá with Tau Deposition in Down Syndrome.mp4
IC-06-04 – Sleep, Cognition, and á-Amyloid in Adults with Down Syndrome.mp4
IC-06-05 – Baseline Amyloid (18F-AV-45 PET) Distributions By Consensus Diagnosis from the Biomarkers.mp4
IC-07-01 – Functional Brain Architecture Predicts Longitudinal Tau Spreading in Alzheimer’s Disease.mp4
IC-07-02 – What Can Structural MRI Tell about aTN Staging.mp4
IC-07-03 – Biomarkers for Capturing Amyloid Independent Effects of Vascular Health on Cognitive Decline.mp4
IC-07-04 – A Topographic Imaging Biomarker of TDP43 Pathology in Amnestic Dementia Based on Autopsy-Derived FDG-PET Patterns.mp4
IS-01 – ISTAART Student Workshop Series Final Title TBD.mp4
IS-02 – ISTAART Student Workshop Series Final Title TBD.mp4
IS-03 – ISTAART Student Workshop Series Final Title TBD.mp4
O1-01-01 – Integrative Proteomics Links Cerebrospinal Fluid Biomarkers to Pathological Networks in Alzheimer’s Disease Brain.mp4
O1-01-02 – Tau Phosphorylation Rates Change from Brain to Cerebrospinal Fluid and Are Differentially Affected By Alzheimer Disease.mp4
O1-01-03 – Plasma Aá42 Aá40 Predicts Hippocampal Atrophy.mp4
O1-01-04 – Identification and Biological Characterization of Extracellular Vesicle Proteins for Propagation and Spread of Tau.mp4
O1-01-05 – Proteomic Assessment of Synapses with Rich Associated Clinical Data Highlight Potential Targets.mp4
O1-01-06 – Neuron-Glia Interaction Markers in Predementia Alzheimer’s Disease.mp4
O1-02-01 – Self-Reported Hearing and Vision Impairment Predicts Dementia in the Oldest Old Pooled Analysis.mp4
O1-02-02 – The Impact of Hearing Loss and Sensory Intervention on the Risk of Progression to Dementia in Mild Cognitive Impairment Cases.mp4
O1-02-03 – Age-Related Hearing Loss and Cognitive Decline in the General Population.mp4
O1-02-04 – Failure to Identify Particular Odours Predicts Future Dementia and Mortality.mp4
O1-02-05 – Dual Sensory Impairment in Older Adults and Risk of Dementia and Alzheimer’s Disease.mp4
O1-02-06 – Association between the Olfactory Identification Ability and Cognitive Function in Non-Demented Elderly.mp4
O1-03-01 – Misfolding and Early Aggregation of Amyloid á42 Protein Critical Role of Membranes.mp4
O1-03-02 – Mechanistic Mathematical Model of the Impact of Anti-Amyloid Beta Drugs and BACE Inhibitors in Alzheimer’s Disease..mp4
O1-03-03 – Predicting Brain Amyloidosis Using Peripheral Blood-Based Gene Expression and Early Stage Neurodegeneration Biomarkers.mp4
O1-03-04 – Cortical Neurons and Cerebral Organoids from APP and PSEN1 Mutation Carriers Reveal ….mp4
O1-03-05 – Induction of Different Brain Pathology in Mice Treated with Two Misfolded Aá Conformers.mp4
O1-03-06 – Pyroglutamation of Aáx-42 and Aá1-40 Deposition Underlie Amyloid Plaque Polymorphism.mp4
O1-04-01 – A Topographic Imaging Biomarker of TDP43 Pathology in Amnestic Dementia Based on Autopsy-Derived FDG-PET Patterns.mp4
O1-04-02 – Early and Late-Onset Alzheimer’s Disease and Suspected Non-Alzheimer Pathophysiology within the aTN Framework.mp4
O1-04-03 – Visually-Rated Structural MRI Profiles in Neuropathologically-Confirmed Chronic Traumatic Encephalopathy.mp4
O1-04-04 – Metabolic Brain Pattern of Creutzfeldt-Jakob Disease and Its Biological Significance.mp4
O1-04-05 – Pathologic Associations of FDG PET in Lewy Body Disease.mp4
O1-04-06 – Cognitive Impairment in in Older Adults with MCI Due to SNAP May be Partially Attributable to Comorbid Conditions.mp4
O1-05-01 – Public Involvement in Research Collaborations in Dementia Care.mp4
O1-05-02 – Nothing about Us without Us Creating the First Canadian Charter of Rights for People with Dementia.mp4
O1-05-03 – Wrap Around Services to Older Adults with Dementia Collaboration, Education, and Prevention.mp4
O1-05-04 – Reaching Individuals Living with Alzheimer’s Disease or Related Dementias from Minority Population.mp4
O1-05-05 – Promoting Dementia Awareness in African American Communities Impact of the Dementia Caring Community Outreach Model.mp4
O1-05-06 – Aging with Pride, IDEA Lessons Learned from the First Tested Clinical Intervention Addressing Dementia.mp4
O1-06-01 – Impact of Healthy Lifestyle Factors on the Risk of Alzheimer’s Dementia; Findings from Two Prospective Cohort Studies.mp4
O1-06-02 – Genetic Risk, Lifestyle and Dementia.mp4
O1-06-03 – Characterization of Cognitive Performance, Gray Matter Volume and White Matter Microstructure.mp4
O1-06-04 – Association between Hypertension and Alzheimer’s Disease and Related Causes of Dementia A Pathways Analysis in the Memento Cohort.mp4
O1-06-05 – Higher Education Provides Resilience Against Deteriorative Effects of Higher Middle Age Body Mass Index on Old Age Cognitive Functioning.mp4
O1-06-06 – The Compensatory Role of Physical Activity on the Association between the ….mp4
O1-07-01 – Longitudinal Evaluation of the Natural History of Aá in Plasma and Brain.mp4
O1-07-02 – Longitudinal Associations between Plasma Nfl and Voxel-Based Morphometry in Alzheimers Disease.mp4
O1-07-02 – Longitudinal Associations between Plasma Nfl and Voxel-Based Morphometry in Alzheimer’s Disease.mp4
O1-07-03 – Longitudinal Plasma Neurofilament Light Is Associated with Rates of Regional Brain Atrophy in Alzheimer’s Disease.mp4
O1-07-04 – CSF Biomarkers of Amyloid, Tau and Synaptic Damage (Neurogranin, SNAP25) and Interneuron-Dependent.mp4
O1-07-05 – Longitudinal Effect of Biological Variables on Plasma NFL and t-Tau Concentrations on Subjective Memory Complainers.mp4
O1-07-06 – Prevalence and Longitudinal Clinical Outcomes of Alzheimer’s ATN Biomarker Profiles A Longitudinal Study.mp4
O1-08-01 – Therapeutic Targeting of TREM2 By an Activating Antibody Ameliorates Amyloid-Beta Deposition.mp4
O1-08-02 – Development of TREM2 Agonistic Antibodies to Treat Alzheimer’s Disease.mp4
O1-08-03 – Targeting NLRP3 Inflammasome with a Novel Inhibitor for Alzheimer’s Disease.mp4
O1-08-04 – Preclinical Development of TREM2 Agonist Antibody (AL002) in Cynomolgus Monkeys.mp4
O1-08-05 – Anti-Inflammatory Effects of SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor in Neurodegenerative Mouse Models.mp4
O1-09-01 – Estimating Years from Clinical Symptom Onset for Sporadic Alzheimer Disease How Far Are We.mp4
O1-09-02 – Two-Period Linear Mixed Effects Primary Analysis Model for Clinical Trials with Run-in Data for Alzheimer Disease.mp4
O1-09-03 – Sex Is Not an Important Predictor of Change in Alzheimer’s Clinical Trial Outcomes.mp4
O1-09-04 – Applying Polygenic Hazard Scores to Enrich Clinical Trial Study Populations of Those at Risk of Alzheimer’s Disease Dementia (ADD).mp4
O1-09-05 – Sexual Dimorphism in Plasma Beta-Secretase 1 Concentrationsin Cognitively Normal Individuals at Risk for AD.mp4
O1-09-06 – Addressing Polypharmacy Issues in an Elderly Population with Cognitive Impairment, Using a Precision-Medicine Platform.mp4
O1-10-01 – Assessing Global and Regional Aá-Amyloid Deposition in the Brain with Multiple Aá-Tracers Using the Centiloid Scale.mp4
O1-10-02 – Longitudinal Analysis of Multivariate Patterns of Amyloid Deposition Reveals Consistent Stages of Amyloidosis across Studies and Tracers.mp4
O1-10-03 – Anatomical Staging of Beta-Amyloid Accumulation Based on Longitudinal Assessment of Globally PIB Negative Adults.mp4
O1-10-04 – Centiloid Cut-Off Values for Optimal Agreement between Amyloid PET and CSF Core AD Biomarkers.mp4
O1-10-05 – Longitudinal Investigation of Concordant and Discordant Amyloid CSFPET Biomarkers Reveals CSF-First.mp4
O1-10-06 – Centiloid Scale in Practice Effect of Different Suvr Reference Regions and Comparison of Centiloid Cut-Offs.mp4
O1-11-01 – Carer’s Appraisal of People with Dementia’s Performance of Daily Tasks What Is the Role of the Carer Management Style.mp4
O1-11-02 – Estimated Impact of Diagnostic Tools for Primary Care Settings on Demand for Specialist Visits for Patients with Prodromal Alzheimer’s Disease.mp4
O1-11-03 – Development and Validation of the Electronic Health Record Risk of Alzheimer’s and Dementia Assessment Rule (eRADAR).mp4
O1-11-04 – The Acceptance of Using Virtual Reality in a Cognitive Stimulation Activity in Older Adults. a Multicenter Randomized Controlled Trial..mp4
O1-11-05 – Effects of a Distraction Method Using a Social Robot on Pain and Anxiety Management in Major Neurocognitive Disorders.mp4
O1-11-06 – High Intensity Telemedicine Reduces Emergency Department Use By Older Adults with Dementia in Senior Living Communities.mp4
O2-01-01 – Brooklyn Cognitive Impairments in Health Disparities Pilot Study.mp4
O2-01-02 – Caregiver Distress from Behavioral Disturbances in Persons with Autosomal Dominant Alzheimer’s Disease Mutations.mp4
O2-01-03 – Abide Delphi Study Topics to Discuss in Diagnostic Consultations in Memory Clinics.mp4
O2-01-04 – Individualized Non-Pharmacological Services Integrating Geriatric Health and Technology (INSIGHT).mp4
O2-01-05 – Designing a Better Visit Touch Screen Apps for People Living with Dementia and Their Visitors.mp4
O2-01-06 – New York State’s Public Health Approach to Alzheimer’s Disease.mp4
O2-02-01 – Different CSF Total and Phosphorylated Tau, but Not Aá, in Older and Younger African Americans and Whites.mp4
O2-02-02 – Comparison of Cognitive, Biomarker and Neuroimaging Characteristics of T+N+ Patients.mp4
O2-02-03 – Stepwise Patient Selection for Amyloid Measurements.mp4
O2-02-04 – CSF Biomarkers in Down Syndrome.mp4
O2-02-05 – Predicting Brain Age As a Biomarker for Risk of Dementia.mp4
O2-02-06 – Cerebrospinal Fluid Based Biomarker Evidence of Amyloidogenesis in Dementia with Lewy Bodies Depends upon ApoE-e4 Carrier Status.mp4
O2-03-01 – Amyloidosis Induces Early Metabolic Reorganization.mp4
O2-03-02 – Derivation and Potential Utility of an Aá PET Imaging Based Weighting Factor for Estimation of Aá Load.mp4
O2-03-03 – Predictors of á-Amyloid Positivity in Cognitively Impaired Patients. Data from the.mp4
O2-03-04 – Defining Amyloid PET Positivity – What If the Coin Had More Than 2 Sides.mp4
O2-03-05 – Prevalence of Clinically Vs. Biologically Defined Alzheimer’s Spectrum Entities Using the National Institute on Aging.mp4
O2-03-06 – Heterogeneity of Amyloid Deposition Pattern Among Amyloid-Positive Cognitively Impaired Individuals.mp4
O2-04-01 – The Role of Astrocytic a7 Nicotinic Acetylcholine Receptors in Neuroinflammation-Mediated Cognitive Impairment.mp4
O2-04-02 – Visualizing Brain Astrocytes – Characterization of 3H-BU99008, an Imidazoline 2 Receptor Ligand, in Human AD Brain.mp4
O2-04-03 – Astrocytosis and Microgliosis Are Early Features of Conditional Mouse Models of ….mp4
O2-04-04 – A Novel Transgenic Rat Model for Mixed Dementia.mp4
O2-04-05 – Predictive Network Analysis Identifies Microglial-Specific Therapeutic Targets for Phagosome.mp4
O2-04-06 – Polymicrobial Infection Exacerbates Neuroinflammation and Worsens Alzheimer’s Associated.mp4
O2-05-01 – Cerebrospinal Fluid Synaptic Vesicle Glycoprotein 2A in Alzheimer’s Disease.mp4
O2-05-02 – Combining Omics and Cognitive Tests Data from the Insight Pre-AD Study, Artificial Intelligence Technology.mp4
O2-05-03 – Characterization and Transfer of a Novel Plasma Aá1-42Aá1-40 Simoa Assay for ….mp4
O2-05-04 – Plasma pTau181 Levels Reflect [18F]AV1451 Tau PET Uptake across the Tauopathy Spectrum.mp4
O2-05-05 – Correlation of CSF Phospholipids and Alzheimer’s Disease Neuropathology.mp4
O2-05-06 – Diagnosing Alzheimer’s Disease through Detection of Tau Protein in Human Blood Using Ultrasensitive.mp4
O2-06-01 – How Do People with Young-Onset Dementia and Their Family Make Decisions and Plan for the Future in Relation.mp4
O2-06-02 – Financial, Legal, and Social Decision-Making in Early-Onset Alzheimer’s Disease.mp4
O2-06-03 – Patterns of Dyadic Appraisal of African American Persons with Dementia Decision-Making and Quality of Life.mp4
O2-06-04 – Ethical Issues Raised By the Introduction of Artificial Companions to Older Adults with Cognitive Impairment A Call for Empowerment.mp4
O2-06-05 – Preliminary Results from the Study of Knowledge and Reactions to Apoe Testing (SOKRATES 2).mp4
O2-07-01 – Sleep Quality and Beta-Amyloid Deposition in Recently Menopausal Women Participating in the Kronos Early Estrogen Prevention Study (KEEPS).mp4
O2-07-03 – Differential Influence of Aging and Alzheimer’s Disease on Sleep and Rest-Activity Rhythms over Entire Adult Life.mp4
O2-07-04 – High Compliance, Continuous Long-Term Home Monitoring of Sleep Activity in Diverse Populations Differentiates Lower.mp4
O2-07-05 – Obstructive Sleep Apnea Severity and Brain Integrity in Ageing A Multimodal ….mp4
O2-07-06 – Sleep-Wake Cycle and 2-Year Changes of Alzheimer’s Disease Neuroimaging Biomarkers and Cognition.mp4
O2-08-01 – Ante-Mortem Volume Loss Mirrors TDP43 Staging in Non-FTLD Older Adults.mp4
O2-08-02 – Early Life Foreign Language Instruction and Late Life Amyloid and Tau Deposition.mp4
O2-08-03 – Long-Term Exposure to Air Pollution and Dementia A Large Clinicopathological Study.mp4
O2-08-04 – Phenotypic Heterogeneity in Familial Alzheimer’s Disease and Associations with Cerebral Amyloid Angiopathy.mp4
O2-08-05 – Pathological Drivers of Neurodegeneration in Suspected Non-Alzheimer’s Pathophysiology.mp4
O2-08-06 – CA2 Neurofibrillary Degeneration and Asymmetry in Primary Age-Related Tauopathy.mp4
O2-09-01 – The Natural History of Alzheimer’s Disease in Down Syndrome.mp4
O2-09-02 – Biphasic Trajectory of Changes for Cortical Thickness and Cortical Mean Diffusivity in Autosomal Dominant Alzheimer’s Disease.mp4
O2-09-03 – Effects of Gene Mutation and Disease Progression on the Structure and Function of Three Cortico-Subcortical Neural Circuits.mp4
O2-09-04 – Single-Subject Grey Matter Networks Deteriorate 12 Years before Dementia.mp4
O2-09-05 – Longitudinal F-AV-1451 Tau PET in Familial Alzheimer’s Disease.mp4
O2-09-06 – Trajectory of Lobar Atrophy in Asymptomatic and Symptomatic Grn Mutation Carriers.mp4
O2-10-01 – Stop-Gain and Non-Synonymous Variants in Novel Genes of an Immune Co-Regulatory Network.mp4
O2-10-02 – Whole Exome Sequencing Analysis in Early Onset Alzheimer Reveals Novel Candidate Genes.mp4
O2-10-03 – Leveraging Tissue Specific Gene Expression Regulation to Identify Genes Associated with Alzheimer’s Disease.mp4
O2-10-04 – Mitochondrial Variants and Haplogroups Associated with Late-Onset Alzheimer’s Disease Identified By Whole Exome Sequencing.mp4
O2-10-05 – Meta-Analysis Employing the African Genome Resources Panel Identifies Novel Alzheimer.mp4
O2-10-06 – Genome-Wide Meta-Analysis of Late-Onset Alzheimer’s Disease Using Rare Variant Imputation in 64,859.mp4
O2-11-01 – Cross-Sectional Associations between CSF Biomarkers of Amyloid and Tau with Neuropsychiatric Symptoms.mp4
O2-11-02 – Neuropsychiatric and Cognitive Symptoms in Alzheimer’s Disease A Study in AD Biomarker Confirmed Patients across the Clinical Spectrum.mp4
O2-11-03 – Behavioral Symptoms Are a Harbinger of Further Cognitive Decline in a 2 Year Longitudinal Study .mp4
O2-11-04 – Towards a Multidimensional Assessment of Apathy in Neurocognitive Disorders.mp4
O2-11-05 – Mild Behavioral Impairment Is Associated with á-Amyloid but Not with Tau in Cognitively.mp4
O2-11-06 – The Course of Apathy in People with Dementia.mp4
O3-01-01 – Interaction between Obesity, Brain HDL, and ApoE4 Genotype in Cerebral Amyloidosis.mp4
O3-01-02 – Chimera Repetitive Mild Traumatic Brain Injury Induces Chronic Behavioral and Neuropathological Phenotypes.mp4
O3-01-04 – Mechanism Securing ‘-Secretase-APP Aá’ Complexes and Regulating Aá Length.mp4
O3-01-05 – Mir-204 Attenuates Memory Deficits in a Mouse Model of Alzheimer’s Disease.mp4
O3-01-06 – Strategy for Development of RNA Aptamers That Target the Toxic Oligomers of Aá42.mp4
O3-02-01 – Apoe-e4 Allelic Load Modulates the Association between CSF Beta-Amyloid and Gray Matter Volume in Cognitively.mp4
O3-02-02 – Amyloid PET, Tau PET, and MRI Measurements in Cognitively Unimpaired Persons with Two, One, & No Copies of the APOE4 Allele.mp4
O3-02-03 – Association between Apoe Isoform and 18-Month Tau Accumulation.mp4
O3-02-04 – APOE Affect the Network Architecture of the Resting Brain in Individuals at Risk for AD.mp4
O3-02-05 – The Association between Apoe 4 and Age-Related Resting State Functional Connectivity in a Community-Base.mp4
O3-02-06 – Cognitively Normal Apoe-e2 Homozygotes Display Greater Hippocampi An Unbiased Voxel-Based Analysis.mp4
O3-03-01 – The Sequence and Timing of Preclinical Cognitive Decline in Autosomal Dominant Alzheimer’s Disease.mp4
O3-03-03 – Change in Cognition Is Correlated with Change in Brain Volumes in Cognitively Normal Older Adults.mp4
O3-03-04 – Divergent Associations between Life Course Cognitive Trajectories and Brain Pathologies Findings from the 1946 British Birth Cohort.mp4
O3-03-05 – Proper Nouns from Story Recall Are Associated with Beta-Amyloid in Cognitively Unimpaired Adults.mp4
O3-03-06 – Biomarkers and Neuropsychological Measures Differentially Predict Risk of Alzheimer’s Dementia for Men and Women.mp4
O3-04-01 – Biomarkers for Capturing Amyloid Independent Effects of Vascular Health on Cognitive Decline.mp4
O3-04-02 – Microvascular Signature of Preclinical Alzheimer’s Disease in a Longitudinal Cohort.mp4
O3-04-03 – MRI Measures of Neurodegeneration and Vascular Injury, but Not Amyloid Status Predict Cognitive Decline.mp4
O3-04-04 – The Impact of Cerebrovascular Disease on the ATN Profile of Young Cognitively Impaired Patients.mp4
O3-04-05 – Distinctive Effects of Amyloid and Tau on Cognitive Decline According to Cerebrovascular Disease Burden.mp4
O3-04-06 – Comorbid Amyloid-á Pathology Affects Neuropsychiatric, Neuropsychological.mp4
O3-05-01 – Genetic Predisposition, Modifiable Risk Factor Profile, and Long-Term Dementia Risk in the General Population.mp4
O3-05-02 – Current and Past Physical Activity and Risk of Alzheimer’s Disease in Older Adults.mp4
O3-05-03 – The Relationship between Adherence to Australian Dietary Guidelines and Brain Health in Older People with and without Type 2 Diabetes.mp4
O3-05-04 – Associations of the Lifestyle for Brain Health (LIBRA) Index with Structural Brain Changes and Cognition Results.mp4
O3-05-05 – The Prevalence and Attributable Risk of Common Important Risk Factors to Inform Strategies for the Population-Based.mp4
O3-05-06 – Global Council on Brain Health Lifestyle Recommendations for Adults 50+.mp4
O3-06-01 – NIH Toolbox Cognition Tablet Battery in Identification of Early Cognitive Impairment.mp4
O3-06-02 – Cognitive and Motor Function in Aging Community-Dwelling Individuals The Rotterdam Study.mp4
O3-06-03 – Awareness of Memory Decline in Asymptomatic at Risk for Alzheimer’s Disease The Meta-Memory Ratio..mp4
O3-06-04 – Evolution and Pathological Basis of Altered Memory Self-Awareness in Cognitively Normal Older Adults.mp4
O3-06-05 – Multiple Memory Tests Substantially Improve Longitudinal Prediction of Progression to Mild Cognitive Impairment.mp4
O3-06-06 – Large-Scale Remote Assessment of Verbal Cognitive Function Using Automatic Speech Recognition..mp4
O3-07-01 – Transmission of Tauopathy Strains Is Independent of Their Isoform Composition.mp4
O3-07-02 – Lysosomal Dysfunction in Stem Cell Models of Tauopathy.mp4
O3-07-03 – Decreased White Matter Fiber Cross-Section Is Associated to Normal Aging and Higher Tau Deposition Independently of Amyloid.mp4
O3-07-04 – Impaired Neural Code of Spatial Information in a Mouse Model of Tau Pathology.mp4
O3-07-05 – Amyloid-Dependent and Amyloid-Independent Effects of Tau on Clinical Status.mp4
O3-07-06 – In Vivo Network Models Highlight Sex-Specific Differences in the Spread of Tau Pathology across Brain Regions.mp4
O3-08-01 – Phenotypes of Cardiovascular Damage and the Association with Cognitive Decline Among Older Adults A Latent Class Analysis Approach.mp4
O3-08-02 – Cardiovascular Risk Factors across the Lifecourse & Cognitive Decline A Pooled Cohort Study.mp4
O3-08-03 – Unsupervised Machine-Learning for Tracking High Likelihood of Dementia in 9 Population-Based Surveys.mp4
O3-08-04 – A Mediation Analysis of the Relationship between White Matter Hyperintensities, CSF Biomarkers.mp4
O3-08-05 – Lifecourse Work-Family Demands and Late-Life Memory Decline Among U.S. Women.mp4
O3-08-06 – Using Genetic Information to Identify Earliest Manifestations of Alzheimer’s Disease.mp4
O3-09-01 – Protective Effect of Physical Activity on Longitudinal Cognitive Decline.mp4
O3-09-02 – White Matter Hyperintensities in Relation to Patterns of Accelerated Brain Aging.mp4
O3-09-03 – Relationship between Midlife Factors and Multimodal Imaging .mp4
O3-09-04 – Age, á-Amyloid and Cognition Selectively Influence Hippocampal Subfield Volume.mp4
O3-09-06 – Cognitive and Brain Resilience to Tau Pathology in Alzheimer’s Disease.mp4
O3-10-01 – Correlation between Amyloid Reduction and Clinical Outcomes Exploratory Analyses.mp4
O3-10-02 – Verubecestat-Induced Brain Volume Loss Occurs Rapidly and Only in Amyloid-Enriched Brain Regions in EPOCH.mp4
O3-10-03 – The Role of Capillary Angiopathy and Aquaporin 4 in ARIA Induced By Aá Immunization.mp4
O3-10-04 – A Statistical Translation of the Public BAN2401 Study Results from a Bayesian to a Traditional Framework.mp4
O3-10-05 – Modulation of microRNA Pathways By Gemfibrozil in Predementia Alzheimer Disease.mp4
O3-11-01 – Informant Ratings, but Not Self-Reports, of Cognitive Decline Predict Amyloid PET Positivity.mp4
O3-11-02 – Latent Class Analysis Identifies Functional Decline with Amsterdam Iadl in Pre-Clinical Alzheimer’s Disease.mp4
O3-11-03 – Subjective Memory Complaint Is Not Associated with Grey-Matter Volume and Brain Activation.mp4
O3-11-04 – Age-Anchoring SCD to Optimize Its Association with CSF AD Biomarkers.mp4
O3-11-05 – Disentangling the Temporal Sequence of Subjective Cognitive Decline, Depressive Symptoms.mp4
O3-11-06 – Subjective Cognitive Decline in and across International Cohort Studies of Ageing The Cosmic Collaboration.mp4
O3-12-01 – Association between Serum Neurofilament Light and Established White.mp4
O3-12-02 – Plasma Amyloid, Inflammatory Markers, and Time to Dementia in the Ginkgo Evaluation of Memory Study.mp4
O3-12-03 – The CSF Synaptic Biomarker BACE1 Correlates with Cognition in MCI and Alzheirmer Disease.mp4
O3-12-04 – Blood-Based Neuro-Inflammation Biomarkers Differentiate Patterns of Vascular Brain Injury.mp4
O3-12-05 – Increased CSF Soluble TREM2 Is Associated with Ameliorated Longitudinal Cognitive and Clinical Decline.mp4
O3-12-06 – Novel CSF Protein Biomarkers for Specific and Differential Diagnosis of AD..mp4
O3-13-01 – Highly Penetrant Late-Onset Alzheimer Disease Variants in NOTCH3 in Ashkenazi Jews.mp4
O3-13-02 – Genome-Wide Linkage Analysis of African-American Alzheimer Disease Families.mp4
O3-13-03 – The Role of ZCWPW1 Susceptibility Locus Rare Variants in Alzheimer’s Disease.mp4
O3-13-04 – Genetic Variants in Alzheimer’s Disease-Associated Regions Have Different Effects.mp4
O3-13-05 – Genetic Study of 404 Pedigrees with Familial Alzheimer’s Disease in China.mp4
O3-13-06 – The MS4A Gene Cluster Is a Key Modulator of Soluble TREM2 and Alzheimer Disease Risk.mp4
O3-14-01 – Increased Adherence to Brain-Healthy Behaviors Is Associated with Improved Quality of Life in Older Adults.mp4
O3-14-02 – The Promoting Activity, Independence and Stability in Early Dementia (PrAISED) Research Programme.mp4
O3-14-03 – A Scoping Review of Behaviour Change Theories in Adults without Dementia to Develop.mp4
O3-14-04 – A Pilot Cluster RCT to Test the Preliminary Efficacy of an Alzheimer’s Family Caregiver Intervention in Hanoi, Vietnam.mp4
O3-14-05 – Our Family Journey Program- an Evidence-Based, Skills Building Mental Health .mp4
O4-01-01 – Inhibiting Amyloid-Beta Cytotoxicity through Its Interaction with the Cell.mp4
O4-01-02 – Structure Based Inhibitors of Amyloid Beta Core Suggest a Common Interface with Tau.mp4
O4-01-03 – Mechanisms of Inhibitors That Block Seeding By Tau from Human Tauopathies.mp4
O4-01-04 – Polymorphism and Toxic Interactions between Soluble Amyloid Oligomers and Tau.mp4
O4-01-05 – Comparative Prionoid and Strain Properties of Tau and Synuclein.mp4
O4-01-06 – Secernin-1 Is a Novel Phosphorylated Tau Binding Protein That Accumulates in Alzheimer’s Disease.mp4
O4-02-01 – Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial.mp4
O4-02-02 – What Are the Effects of Benzodiazepine and Anticholinergic Drug Use on the Brain- Neuropathological Study.mp4
O4-02-03 – Randomized Trial of Suvorexant for Treating Insomnia in Alzheimer’s Disease Effects on Objective Sleep Measures.mp4
O4-02-04 – Exploring Gut Microbiota As a Source of Potential Biomarkers Initial Results from the Anavex.mp4
O4-02-05 – Continued Innovations in Study Start up (SSU)Ongoing Progress of the GAP Foundation on Site Start up.mp4
O4-02-06 – Oral Treatment with RD2 Reduces AB Oligomer Load, Enhances Cognition, Decelerates.mp4
O4-03-01 – Frontotemporal Lobar Degeneration Research in North AmericaProgress in the ArtflLefftds Consortia.mp4
O4-03-02 – Differentiating Frontotemporal Dementia from Alzheimer’s Disease on Measures of Empathy.mp4
O4-03-03 – Clinical Characterization of Mild Cognitive Impairment Associated with Eventual Lewy Body Disease Pathology.mp4
O4-03-04 – Profile of and Risk Factors for Post-Stroke Cognitive Impairment in Diverse Ethno-Regional Groups.mp4
O4-03-05 – Longitudinal Cognitive Decline and Prodromal Staging Model for Alzheimer’s Disease in Down Syndrome.mp4
O4-03-06 – Longitudinal Association between Apathy and Cognitive Decline.mp4
O4-04-01 – What Can Structural MRI Tell about aTN Staging.mp4
O4-04-02 – Identification of Fast Converters Among MCI Patients By Integrating Incomplete.mp4
O4-04-03 – The Biological Basis of Cognitive Impairment Due.mp4
O4-04-04 – Pib(+) Chronicity Provides Unique Information about Cognitive Decline and NFT Development.mp4
O4-04-05 – Microglial Activation and Tau Burden Predict Cognitive Decline in Alzheimer’s Disease.mp4
O4-04-06 – Amyloid PET Is More Than Just Positive or Negative Amyloid Level Impacts Risk of Clinical Progression in Normal Individuals..mp4
O4-05-01 – Apolipoprotein e4 Allele Effects on Longitudinal Cognitive Trajectories Are Sex- and Age-Dependent.mp4
O4-05-02 – Does the Effect of Education on Cognition Differ across RacialEthnic Groups Evidence from the Kaiser Healthy Aging.mp4
O4-05-03 – A Longitudinal Study of the Effects of Education and Intracranial Volume.mp4
O4-05-04 – Subclinical Cardiovascular Dysfunction Is Associated with Increased Cerebrospinal Fluid ….mp4
O4-05-05 – Social Support and Cognitive Function in Type 1 Diabetes Findings from the Study of Longevity in Diabetes (SOLID) Study.mp4
O4-05-06 – Invariance Measurement of Neuropsychological Tests across Different Sociodemographic Background.mp4
O4-06-02 – Fitness for the Ageing Brain Study (FABS) Long-Term Follow-up Stage 1.mp4
O4-06-03 – Exploring Individual Variability in Exercise-Induced Cognitive Change.mp4
O4-06-04 – Precision Medicine Intervention in Patients at Risk for Alzheimer’s Dementia.mp4
O4-06-05 – Promoting a Brain-Healthy Lifestyle for Reducing the Risk of Cognitive Decline and Dementia Libra and the Mijnbreincoach.mp4
O4-06-06 – An Evaluation of the Implementation of Mybrainrobbie in School-Age Children in France.mp4
O4-07-01 – Trends in Dementia Prevalence, Incidence and Mortality in the United States.mp4
O4-07-02 – Trends in Incident Dementia and Early Life Environment By Birth Cohort.mp4
O4-07-03 – Birth Cohort Analysis of Trends in Amnestic Mild Cognitive Impairment (MCI).mp4
O4-07-04 – Subjective Cognitive Decline Higher Among Sexual and Gender Minorities Population-Based Findings from Nine States in the U.S..mp4
O4-07-05 – NIA-AA Research Framework Application to the French Population By Inference from the Memento Cohort.mp4
O4-08-01 – Unmet Needs Among Americans Living Alone with Dementia A Population-Based Study.mp4
O4-08-02 – Priorities and Concerns of Older Latinos Living Alone with Cognitive Impairment An in-Depth Perspective.mp4
O4-08-03 – Village Infrastructure, Community Facilities and Its Effect on Cognitive Function Among Older Adults in Rural China Evidence from the Baseline.mp4
O4-08-04 – Where Do I Fit in the Impact of Gentrification on Aging in Place.mp4
O4-08-05 – Well-Being and Quality of Life in Mild Cognitive Impairment The Influence of Social Networks, Loneliness and Spirituality.mp4
O4-08-06 – Neighborhood Park Space and Cognition in Non-Demented Older Adults The Multi-Ethnic Study of Atherosclerosis.mp4
O4-09-01 – Leveraging Mouse Genetic Diversity to Investigate the Role of Brain Myeloid Cells in Alzheimer’s Disease.mp4
O4-09-02 – Regulation of Pro-Inflammatory and Disease-Associated Microglial Activation By Bin1.mp4
O4-09-03 – Immunosuppression Exacerbates Alzheimer’s Disease Pathology in APP PS1 Transgenic Mice.mp4
O4-09-04 – Upregulation of SOCS3 By Aspirin in Brain Cells Via PPAR-Alpha.mp4
O4-09-05 – Inteleukin-10 Induces Metabolic Changes Driving Aá Immune Tolerance in Macrophages.mp4
O4-09-06 – Clonally Expanded CD8 T Cells Patrol Alzheimer’s Cerebrospinal Fluid.mp4
O4-10-01 – Characterizing Cell Type-Specific Expression Signatures in Brain Using Single Cell RNA Sequencing.mp4
O4-10-02 – Dysregulated Fc Gamma R-Mediated Phagocytosis Pathway in Alzheimer’s Disease Network-Based Gene Expression Analysis.mp4
O4-10-03 – Functional Dissection of Alzheimer’s Disease Brain Gene Expression Signatures in Humans and Mouse Models.mp4
O4-10-04 – Large-Scale Proteomic Analysis of Human Prefrontal Cortex Identifies Proteins Associated with Cognitive Trajectory in Advanced Age.mp4
O4-10-05 – Multi-Omic Analysis Identifies Transcriptional Networks and Drivers Associated with Cognitive Aging and Alzheimer’s Disease.mp4
O4-10-06 – Integrated Genetic-Epigenetic Analyses of Alzheimer’s Disease.mp4
O4-11-01 – World Wide Fingers A Global Collaboration for Future Generations.mp4
O4-11-02 – NSAIDs for AD Prevention Naproxen Enters the CNS without Apparent Effect on CSF Immune Markers.mp4
O4-11-03 – U.S. Pointer Study Design and Launch.mp4
O4-11-04 – Linking Diabetes and Alzheimer’s Disease through RAGE. a Retrospective Analysis of Azeliragon Phase 2 and Phase 3 Studies.mp4
O4-11-05 – A Proof of Concept Phase II Study Repurposing Atomoxetine for Neuroprotection in Mild Cognitive Impairment Evidence.mp4
O4-11-06 – Defining Cognition in Pre-Dementia Clinical Trials Baseline Neuropsychological Data from the TOMMORROW Study.mp4
O4-12-01 – Tau PET Imaging Correlates with Neuropathology.mp4
O4-12-02 – Tau Pathology and Cognition Are Related to Basal Forebrain Degeneration in Aging.mp4
O4-12-03 – Cortical Tau Deposition Follows Patterns of Entorhinal Functional Connectivity in Cognitively Normal Older Adults.mp4
O4-12-04 – Cerebrospinal Fluid and PET Measures of Tau Pathology Indicate Different State of AD Pathophysiological Progression.mp4
O4-12-05 – Evaluation of Tau Deposition in Amyloid Positive MCI or Mild-AD Dementia Subjects from the Elenbecestat Mission AD Program.mp4
O4-12-06 – Automated Reporting of Tau PET Quantification on Brain Surface.mp4
O4-13-01 – Early Adulthood Vascular Risk Strongly Predicts Brain Volumes and White Matter Disease, but Not Amyloid Status, at Age 69-71 Year.mp4
O4-13-02 – Mid- and Late-Life Physical Activity and Brain Amyloid Deposition The Atherosclerosis Risk in Communities (ARIC)-PET Study.mp4
O4-13-03 – Plasma Amyloid-á Monomers and the Risk of Clinical Cardiovascular Disease in the General Population The Rotterdam Study.mp4
O4-13-04 – The Association between Particulate Matter and Episodic Memory Decline Is Partially Mediated By Early Neuroanatomic Biomarkers.mp4
O4-13-05 – Brain Correlates of Air Pollution in Cognitively Healthy Individuals at Risk of Alzheimer’s Disease.mp4
O4-13-06 – Associations between Multimorbidity and CSF Amyloid Cross-Sectional Analysis of the European Prevention of Alzheimer’s Dementia.mp4
O5-01-01 – Head-to-Head In Vivo Comparison of Tau Positron Emission Tomography Ligands 18f-Flortaucipir and 18f-RO948.mp4
O5-01-02 – Functional Brain Architecture Predicts Longitudinal Tau Spreading in Alzheimer’s Disease.mp4
O5-01-03 – Early Tau PET Pathology Is Associated with Memory Performance in Cognitively Unimpaired Individuals with SCD The Science Project.mp4
O5-01-04 – Patterns of Tau Pathology Identified with 18f-MK-6240 PET Imaging.mp4
O5-01-05 – Tau Imaging with 18f-MK6240 in Alzheimer’s Disease and Other Dementias.mp4
O5-01-06 – Early Tau Detection and Implications for Disease Progression.mp4
O5-02-01 – Genome-Wide Association Study of Plasma Tau Levels Using Hrc Imputations in the Framingham Study.mp4
O5-02-02 – Differential Expression of Polygenic Risk in Cerebrospinal Fluid Proteomic Measures in Alzheimer’s Disease.mp4
O5-02-03 – Onset Age Modifier for GRN-Associated Frontotemporal Lobar Degeneration.mp4
O5-02-04 – Integrative Genomic Profiling to Identify Genes and Pathways Associated with Vascular Risk in AD..mp4
O5-02-05 – Genome-Wide, Stage-Specific Association across Alzheimer’s Disease Endophenotypes Modeling SNP By Diagnosis Interactions.mp4
O5-02-06 – Genetic Association and Characterization of CCRL2-V180M with Alzheimer’s Disease, Cognitive Decline, and Serum Cytokine Levels..mp4
O5-03-01 – Affordable EEG Markers for the Screening of Cognitive Impairment of Old Adults.mp4
O5-03-02 – Electroretinography in Pre-Clinical Alzheimer’s Disease An Electrophysiologic Assessment of the Retina As an Early Detection Ocular.mp4
O5-03-03 – The Subclinical-Clinical Spectrum of Hyperexcitability in Alzheimer’s Disease An Ambulatory Scalp EEG Study.mp4
O5-03-04 – Abnormalities of Electroencephalographic (EEG) Markers in Quiet Wakefulness Are Related to Motor Deficits, Cognitive Symptoms.mp4
O5-03-05 – Retinal Nerve Fiber Layer Thinning in Pre-Clinical Alzheimer’s Disease Predicts CSF Amyloid Tau Classification.mp4
O5-03-06 – Do Odor Identification and Remote Odor Memory Together Predict Conversion from MCI to AD in ApoE e4 Carriers.mp4
O5-04-01 – TRIM46 Knockdown Causes Neuronal Tau Redistribution and Increases Axosomatic Tau Diffusion.mp4
O5-04-02 – Traumatic Brain Injury Induces Tau Aggregation and Spreading.mp4
O5-04-03 – Relevance of Tau Seeding for the Clinical Heterogeneity of Alzheimer’s Disease, Implication for Therapeutic Perspectives.mp4
O5-04-04 – Accumulation of Modifications in the Tau Core Region during the Tau Aggregation Process in Alzheimer’s Disease.mp4
O5-04-05 – A New Therapeutic Strategy for Tauopathies- Discovery of Highly Potent Brain Penetrant PROTACTM Degrader Molecules That Target.mp4
O5-04-06 – Tau Associates with Ribosomal Proteins Shifting the Translatome.mp4
O5-05-01 – Multivariate Patterns of Association between Diffusion Imaging Metrics and Plasma Neurofilament Light in Prodromal Alzheimer’s Disease.mp4
O5-05-02 – CSF Biomarkers of Synaptic Damage (Neurogranin, SNAP25) and Interneuron-Dependent Synaptic Homeostasis (NPTX2)I.mp4
O5-05-03 – Associations between Cerebrospinal Fluid Neurodegenerative Markers Neurofilament-Light and Total Tau and Cerebrovascular Imaging Markers.mp4
O5-05-04 – Plasma Neurofilament Light Measurements in More Than 2,100 Presenilin-1 E280A Mutation Carriers and Non-Carriers from the World’s.mp4
O5-05-05 – Undulations of the Plasma Proteome Define Distinct Stages of Human Lifespan and Reveal Accelerated Aging in Alzheimer’s Disease.mp4
O5-06-01 – Selective Targeting of Amyloid-Beta Oligomer Species By PMN310, a Monoclonal Antibody Rationally Designed for Greater Therapeutic Potency.mp4
O5-06-02 – Axonal Organization Defects in the Hippocampus of Adult Conditional BACE1 Knockout Mice Implications for BACE1 Inhibitor Clinical Trials.mp4
O5-06-03 – Small Molecules Targeting Tau Aggregation Decrease Tau Pathology and Neuroinflammation In Vivo.mp4
O5-06-04 – Characterization of Novel Tau-Specific Antibodies and Enhancement of Their Delivery into the Brain Using Focused Scanning Ultrasound.mp4
O5-06-05 – Improved Intrathecal Vector Delivery for Gene Therapy in Alzheimer’s Disease.mp4
O5-06-06 – Ligands of the Core Acetylcholine Biosynthesizing Enzyme, Choline Acetyltransferase As Novel and Potential Therapeutic Agents.mp4
O5-07-01 – Global Cortical [F18]Flortaucipir Association with the Top 20 Alzheimer’s Disease Risk Genes.mp4
O5-07-02 – Apolipoprotein E and BIN1 Polymorphisms Differentially Affect Cortical Amyloid and Tau Load in Healthy Older Adults.mp4
O5-07-03 – Integrating Genetics and Brain Imaging to Improve Alzheimer’s Disease Risk Prediction.mp4
O5-07-04 – Combining Omics and Imaging Data from the Insight Pre-AD Study, Artificial Intelligence Technology Identifies Genomic.mp4
O5-07-05 – GWAS of Hippocampal Subfield and Neighboring Cortical Structure Volumes Identifies an ERC1 Locus Using ADNI High-Resolution MRI Data.mp4
O5-07-06 – The Heritability of Amyloid Deposition and Its Shared Genetic Basis with Small Vessel Disease in the Brains of Older People.mp4
O5-08-01 – Trends in Racial and Ethnic Differences in Dementia Prevalence Rates and Disease Awareness.mp4
O5-08-02 – Costs of Alzheimer’s Disease and Dementia in 188 Countries.mp4
O5-08-03 – Trajectories of Health System Use and Survival for Community-Dwelling Persons with Dementia An Inception Cohort Study.mp4
O5-08-04 – A New Open-Source Modeling Framework to Assess Cost Effectiveness of Early Intervention in Alzheimer’s Disease..mp4
O5-08-05 – Structural Uncertainty and Cross-Validation of Decision Models in the AD Setting Answering Questions from Policy Makers on the Reliability.mp4
O5-08-06 – Cost-Effectiveness of a Collaborative Dementia Care Management – Results of a Cluster-Randomized Controlled Trial.mp4
O5-09-01 – Gender Differences in Mental Status Trajectories across Adulthood Are Men More Resilient Than Women.mp4
O5-09-02 – Duration of Dementia and Formal Care Use Effects of Age, Gender, Living Situation, Dementia Medication and Ethnicity.mp4
O5-09-03 – Sex Differences in Dementia Evidence from Population-Based Studies and the Finger Lifestyle Intervention.mp4
O5-09-04 – Validity of Algorithmic Diagnoses of Dementia A Case Study of Application to Research on Race Ethnic Disparities in Dementia.mp4
O5-09-05 – Racial and Ethnic Differences in Dementia Diagnosis Following Cognitive Decline Insights from Linked Survey and Health Care Claims Data.mp4
O5-09-06 – Race Modifies the Association between Sleep Disturbance, Cognitive Decline and Alzheimer’s Disease Biomarkers Among Cognitively.mp4
O5-10-01 – Enhanced Function of PLCg2 Variant P522R in Macrophages and Microglia Is Associated with Protection from Alzheimer’s Disease.mp4
O5-10-02 – The Transcriptional Landscape of Microglial Genes in Aging and Neurodegenerative Disease.mp4
O5-10-03 – Mapping Genome Repair Hotspots in Post-Mitotic Human Neurons.mp4
O5-10-04 – Dysregulation of NSUN2 Promotes Pathological Tau Alterations in Alzheimer’s Disease.mp4
O5-10-05 – Novel Insights of Tau RNA-Protein Biology in the Precipitating Role of Chronic Stress on Alzheimer’s Disease Brain Pathology..mp4
O5-10-06 – Loss of Neuroprotective MiR-219 Reveals a Dysregulated Tau Kinase Network in Alzheimer’s Disease.mp4
PL-01-01 – Plenary Session Association Welcome.mp4
PL-01-02-01 – Understanding the Earliest Phases of Alzheimer’s Disease.mp4
PL-03-01 – Plenary Session Inge Grundke-Iqbal Award for Alzheimer’s Research Neurotoxic Reactive Astrocytes Are Induced.mp4
PL-04-01-01 – Imaging Neurodegeneration with MRI What Is New.mp4
PL-04-02-01 – The Cellular Phase of Alzheimer’s Disease.mp4
S1-01-01 – Dementia Prevention Programs in Urban and Regional Aboriginal Communities in Australia.mp4
S1-01-02 – Health Literacy and Access to Dementia Care.mp4
S1-01-03 – Improving the Lives of People with Dementia The OECD Perspective.mp4
S1-01-04 – Dementia As Access Barrier in Palliative Care.mp4
S1-02-01 – Clustering of Rare Variants in Alzheimer Disease and Related Disorders in the Colombian Population A Genomic Study.mp4
S1-02-02 – The Potential Contribution of Rare Variants to Neurodegenerative Brain Dementia.mp4
S1-02-03 – Whole-Exome Sequencing in 20,197 Persons for Rare Variants in Alzheimer’s Disease.mp4
S1-02-04 – High-Throughput Identification of Noncoding Functional SNPs.mp4
S2-01-01 – PET Markers of Microglia.mp4
S2-01-02 – PET Markers of Astrocytes.mp4
S2-01-03 – Neuroinflammation CSF Perspective.mp4
S2-01-04 – Fluid Biomarkers of Neuroinflammation.mp4
S2-02-01 – Precision Medicine Model for Targeted NSAID Therapy in AD.mp4
S2-02-03 – Insulin-Resistant Sub-Typing.mp4
S2-02-04 – Subtyping of Clinical Subjects through Exosome Analyses.mp4
S3-01-01 – Alzheimer’s and Vascular Disease A Pathobiological Perspective.mp4
S3-01-02 – Alzheimer’s Disease and Subcortical Vascular Cognitive Impairment (SVCI) Biomarker Perspective.mp4
S3-01-03 – Alzheimer’s and Lewy Body Disease Pathologic Perspective.mp4
S3-01-04 – Alzheimer’s and Lewy Body Disease Biomarker Perspective.mp4
S3-02-01 – Statistical Challenges with Responder Analysis in Exploratory Settings.mp4
S3-02-02 – Multi-Crossover Randomized Control Design Approaches Based on Analyses of ResponderNon-Responder Outcomes.mp4
S3-02-03 – Statistical Considerations for Efficient Designs within a Platform Trial Approach.mp4
S3-02-04 – Determining Whether Identification of a Responder Sub-Group is Truly Hypothesis Generating.mp4
S4-01-01 – ?Identifying Elders at risk for Cognitive Decline using the Brain Health Registry BHR.mp4
S4-01-02 – The Dutch Brain Health Registry for Recruitment of Research Participants.mp4
S4-01-03 – Swedish Clinical Quality Registry for Dementia.mp4
S4-01-04 – The Australian Dementia Network (ADNet) Clinical Quality Registry.mp4
S5-01-01 – Description and Impact of Delirium on Dementia.mp4
S5-01-01 – Immunotherapy in Alzheimer Disease Mechanisms of Monoclonal Antibodies in Development.mp4
S5-01-02 – Biomarkers in Delirium.mp4
S5-01-03 – Neurobiology of Delirium and Its Intersection with Dementia Insights from Animal Models.mp4
S5-01-04 – Systemic Inflammation Signaling to the Brain.mp4
TD-03-01 – Gait Impairments in Dementia Subtypes Considering the Impact of Environmental Context.mp4
TD-03-03 – Developing an Electronic Consent for ADRC.mp4
TD-03-04 – High Compliance, Continuous Long-Term Home Monitoring of Sleep Activity in Diverse Populations.mp4
TD-04-01 – Mobile Monitoring of Cognition in Middle-Aged and Older Adults with and without Amnestic Mild Cognitive Impairment.mp4
TD-04-04 – Augmented Reality Technology for People with Dementia.mp4
TD-04-05 – A Cross-Comparison and Validation of Four Computer-Administered Neuropsychological Assessment.mp4
TD-04-06 – Gamechanger Can Digital Biomarkers Transform the Detection of Preclinical Alzheimer’s Disease.mp4
TD-04-07 – Identifying Prodromal Features of Dementia in UK Primary Care A Nested Case-Control Study.mp4
TD-04-08 – GENFI Ignite A Novel Cognitive Assessment App for Testing Presymptomatic Frontotemporal Dementia.mp4
TD-04-09 – AI-Based Digital Phenotyping of Behavioral and Psychiatric Symptoms in Dementia Clinical Implications.mp4
TD-04-10 – Development and Usability of ADappt – an Online Tool to Support Clinicians, Patients and Caregivers.mp4
TD-04-11 – Delivering Disease Progression Models to Clinical Practice A User Study on Opportunities and Barriers for Translation and Adoption.mp4
TD-04-12 – Identifying Individuals with Dementia, MCI and Physical Impairment during Group Activities.mp4
TD-04-13 – Using Participatory Design & Community Engagement to Develop Online Caregiver Support.mp4
TD-04-14 – The Challenges of Monitoring Subject Adherence to Study Protocols in Technology-Based Aging and Dementia Clinical Research Studies.mp4
TD-04-15 – Unobtrusive, Sensor-Based Measurement of in-Home Walking Speed and Its Day-to-Day Variability Identifies Future Falls in Older Adults.mp4

Reviews

There are no reviews yet.

Be the first to review “Alzheimer’s Association International Conference 2019”

Your email address will not be published.